Expression of the antiapoptotic protein bcl-2 is not dependent on the tumor suppressor p53 protein in indian breast carcinoma

Pathobiology

Volumn 65, Issue 2, 1997, Pages 108-112

  Kesari, A Lakshmi ^a   Chellam, V G ^c   Madhavan, Jayaprakash ^b   Nair, P P ^d   Nair, M Krishnan ^b   Pilla, M Radhakrishna ^a  

^a Division of Laboratory Medicine   (India)

^b Regional Cancer Center   (India)

^c Departments of Pathology and Surgery   (India)

^d Medical College Hospital Thiruvananthapuram   (India)

Author keywords

Bcl 2; Breast cancer; p53; PCNA

Indexed keywords

CYCLINE; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER GROWTH; CELL DEATH; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE MUTATION; HOMEOSTASIS; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; INDIA; MAJOR CLINICAL STUDY; PATHOGENESIS; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; BREAST NEOPLASMS; CARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INDIA; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031009511     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000164111     Document Type: Article

References (22)

1. Williams GT: Programmed cell death: Apopto-sisand oncogenesis. Cell 1991;65:1097-1098.
2. Ellege RM, Allred DC: The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 1994;32:39-47.
3. Lin D, Sheilds MT, Ullrich ST, Apella E, Mercer WE: Growth arrest induced by wild type p53 protein blocks cells prior to or near the restriction point in late GI phase. Proc Natl Acad Sci USA 1992:89:9210-9214.
4. Me Donnel AR, Marin TJ, Brisbay MC, McConncl K, Tu SM, Cambell ML, Rodriguez VJ: The bcl-2 oncogene, apoptosis and neoplasia. Radiat Res 1993;136:307-312.
5. Sierra A, Liovcras B, Casiellsague X, Moreno L, Ramirez MG, Fabra A: Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinomas. Int J Cancer 1995:60:54-60.
6. Kesari AL, Radhakrishnan R, Bhanumathi A, Ravi D, Srinivas G, Nair MK, Pillai MR: Expression of epidermal and transforming growth factors in pancreatic cancer. Oncol Rep 1996:3:963-966.
7. Van den Berg FM, Bass IO, Polak MM, Offerhaus GJA: Detection of p53 overexpression in routinely fixed paratlin embedded tissue of human carcinomas using a novel targeting unmasking fluid. Am J Pathol 1993; 142:381-385.
8. Ellis PA, Smith IE, Dowsett M: Apoptosis-its role in tumor growth and therapy. Cytopatho-logy 1996:22:132-135.
9. Ravi D, Nalinakumari KR, Rajaram RS, Nair MK, Pillai MR: Expression of programmed cell death regulatory p53 and bcl-2 proteins in oral lesions. Cancer Lett 1996:105:139-146.
10. Pillai MR, Halabi S, McKalip A, Jayaprakash PG, Rajalakshmi TN, Nair MK, Herman B: The presence of human papillomavirus-16/18 E6, p53, and bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer. Cancer Epidemiol Biomarkers Prev 1996;5:329-335.
11. Silvestrini R, Benini E, Veneroni S, Daidonc MG, Tomasic G, Squicciarini P, Salvadori B: p53 and bcl-2 expression correlates with clinical outcome in a series of lymph node positive breast cancer patients. J Clin Oncol 1996:14: 1604-1610.
12. Haider S, Negrini M, Monne M, Sabbioni S, Croce CM: Down regulation of bcl-2 and p53 in breast cancer cells. Cancer Res 1994:54: 2095-2097.
13. Selvakumaran M, Lin HK, Miyashila T, Wang HG, Kravewski S, Reed JC, Hoffmann B, Lie-bermann D: Immediate early up-regulation of bax expression by p53 but not TGF beta I: A paradigm for distant apoptotic pathways. Oncogene 1994:9:1791-1798.
14. Miyashita T, Harigai M, Hanada M, Reed JC: Identification of a p53 dependent negative response element in the bcl2 gene. Cancer Res 1994:54:3131-3135.
15. Davidoff AM, Humprey PA, Iglehart JD, Marks JR: Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 1991:88:5006-5011.
16. Watson AJM, Merritt AJ, Jones LS, Askew JN, Anderson E, Bccciolin A, Balzi M, Potten CS, Hickman JA: Evidence forreciprocalityofbcl2 and p53 expression in human colorectal adenomas and carcinomas. Br J Cancer 1996:73: 889-895.
17. Nathan B, Gusterson B, Jadayel D, Hare O, Anbazhagan R, Jayathilake H, Ebbs S, Micklem K, Prie K, Gelber R, Reed R, Senn HJ, Goldhirsch A, Dyer MJS: Expression of bci2 in primary breast cancer and its correlation with tumor phenotype. Ann Oncol 1994,5:409-414.
18. Kesari AL, Chellam VG, Thomas PA, Nair PP, Sebastian P, Madhavan J, Nair MK, Pillai MR: p53 tumor suppressor protein and tissue proliferative fraction in infiltrating duct carcinoma. J Surg Oncol 1997, in press.
19. Deppert W: The yin and yang of p53 in cellular proliferation. Sent Cancer Biol 1994,5:187-202.
20. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, C'hamness GC, Osborne CK, Mcgurie WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node negative breast cancer. J Natl Cancer Inst 1993:85:200-206.
21. Cattoretti G, Rilke F, Andreola SD, Amato L, Delia D: p53 expression in breast cancer. Int J Cancer 1988;41:178-183.
22. Martinez J, Gcorgoff I, Martinez J: Cellular localization and cell cycle regulation by a temperature sensitive p53 protein. Genes Dev 1991;5:151-159.